BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 32640312)

  • 41. The hematopoietic cell transplantation-specific comorbidity index fails to predict outcomes in high-risk AML patients undergoing allogeneic transplantation--investigation of potential limitations of the index.
    Birninger N; Bornhäuser M; Schaich M; Ehninger G; Schetelig J
    Biol Blood Marrow Transplant; 2011 Dec; 17(12):1822-32. PubMed ID: 21708108
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Allogeneic stem cell transplantation following relapse post autologous stem cell transplantation in adult patients with acute myeloid leukemia: A retrospective analysis of 537 patients from the Acute Leukemia Working Party of the EBMT.
    Christopeit M; Labopin M; Gorin NC; Saraceni F; Passweg J; Forcade E; Maertens J; Van Lint MT; Bosi A; Niederwieser D; Ehninger G; Polge E; Mohty M; Nagler A
    Am J Hematol; 2018 Dec; 93(12):1532-1542. PubMed ID: 30218444
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cytomegalovirus reactivation in lymphoma and myeloma patients undergoing autologous peripheral blood stem cell transplantation.
    Massoud R; Assi R; Fares E; Haffar B; Charafeddine M; Kreidieh N; Mahfouz R; Kanj SS; El Zakhem A; Kharfan-Dabaja M; Bazarbachi A; El Cheikh J
    J Clin Virol; 2017 Oct; 95():36-41. PubMed ID: 28843110
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mortality patterns among recipients of autologous hematopoietic stem cell transplantation for lymphoma and myeloma in the past three decades.
    Bhatt VR; Loberiza FR; Jing H; Bociek RG; Bierman PJ; Maness LJ; Vose JM; Armitage JO; Akhtari M
    Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):409-415.e1. PubMed ID: 25816932
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hematopoietic Stem Cell Transplant Recipients Surviving at Least 2 Years from Transplant Have Survival Rates Approaching Population Levels in the Modern Era of Transplantation.
    Kliman D; Nivison-Smith I; Gottlieb D; Hamad N; Kerridge I; Purtill D; Szer J; Ma D
    Biol Blood Marrow Transplant; 2020 Sep; 26(9):1711-1718. PubMed ID: 32194285
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.
    Keller JW; Andreadis C; Damon LE; Kaplan LD; Martin TG; Wolf JL; Ai WZ; Venstrom JM; Smith CC; Gaensler KM; Hwang J; Olin RL
    J Geriatr Oncol; 2014 Jul; 5(3):238-44. PubMed ID: 24894413
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of Late Toxicities on Outcomes in Long-Term Survivors of Ex-Vivo CD34
    Scordo M; Shah GL; Kosuri S; Herrera DA; Cho C; Devlin SM; Maloy MA; Nieves J; Borrill T; Avecilla ST; Meagher RC; Carlow DC; O'Reilly RJ; Papadopoulos EB; Jakubowski AA; Koehne G; Gyurkocza B; Castro-Malaspina H; Tamari R; Perales MA; Giralt SA; Shaffer BC
    Biol Blood Marrow Transplant; 2018 Jan; 24(1):133-141. PubMed ID: 28870777
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Modified EBMT Pretransplant Risk Score Can Identify Favorable-risk Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for AML, Not Identified by the HCT-CI Score.
    Michelis FV; Messner HA; Uhm J; Alam N; Lambie A; McGillis L; Seftel MD; Gupta V; Kuruvilla J; Lipton JH; Kim DD
    Clin Lymphoma Myeloma Leuk; 2015 May; 15(5):e73-81. PubMed ID: 25458081
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi.
    Olivieri J; Mosna F; Pelosini M; Fama A; Rattotti S; Giannoccaro M; Carli G; Tisi MC; Ferrero S; Sgherza N; Mazzone AM; Marino D; Calimeri T; Loseto G; Saraceni F; Tomei G; Sica S; Perali G; Codeluppi K; Billio A; Olivieri A; Orciuolo E; Matera R; Stefani PM; Borghero C; Ghione P; Cascavilla N; Lanza F; Chiusolo P; Finotto S; Federici I; Gherlinzoni F; Centurioni R; Fanin R; Zaja F;
    Biol Blood Marrow Transplant; 2018 Sep; 24(9):1814-1822. PubMed ID: 29857196
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34
    Barba P; Ratan R; Cho C; Ceberio I; Hilden P; Devlin SM; Maloy MA; Barker JN; Castro-Malaspina H; Jakubowski AA; Koehne G; Papadopoulos EB; Ponce DM; Sauter C; Tamari R; van den Brink MRM; Young JW; O'Reilly RJ; Giralt SA; Perales MA
    Biol Blood Marrow Transplant; 2017 Jan; 23(1):67-74. PubMed ID: 27789361
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Age Adjusted Comorbidity Risk Index Does Not Predict Outcomes in an Autologous Hematopoietic Stem Cell Transplant Population.
    Barth D; Singleton M; Monohan G; McClune B; Adams V
    Cell Transplant; 2022; 31():9636897221080385. PubMed ID: 35225031
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Outcome of autologous hematopoietic stem cell transplant in older patients with B cell lymphoma when selected for fitness and chemosensitive disease.
    Lemieux C; Ahmad I; Bambace NM; Bernard L; Cohen S; Delisle JS; Fleury I; Kiss T; Mollica L; Roy DC; Sauvageau G; Roy J; Lachance S
    Leuk Res; 2019 Apr; 79():75-80. PubMed ID: 30654975
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Performance status, but not the hematopoietic cell transplantation comorbidity index (HCT-CI), predicts mortality at a Canadian transplant center.
    Guilfoyle R; Demers A; Bredeson C; Richardson E; Rubinger M; Szwajcer D; Seftel MD
    Bone Marrow Transplant; 2009 Jan; 43(2):133-9. PubMed ID: 18762762
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Role of HCT-comorbidity index, age and disease status at transplantation in predicting survival and non-relapse mortality in patients with myelodysplasia and leukemia undergoing reduced-intensity-conditioning hemopoeitic progenitor cell transplantation.
    Bokhari SW; Watson L; Nagra S; Cook M; Byrne JL; Craddock C; Russell NH
    Bone Marrow Transplant; 2012 Apr; 47(4):528-34. PubMed ID: 21743502
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Improvement over the years of long-term survival in high-risk lymphoma patients treated with hematopoietic stem cell transplantation as consolidation or salvage therapy.
    Calderón-Cabrera C; Márquez-Malaver FJ; de la Cruz-Vicente F; Falantes F; Carrillo E; Parody R; Montero I; González Campos J; Martino ML; Carmona M; Pérez-Simón JA; Espigado I
    Transplant Proc; 2013; 45(10):3665-7. PubMed ID: 24314990
    [TBL] [Abstract][Full Text] [Related]  

  • 56. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
    Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Jan; 1():CD007678. PubMed ID: 22258971
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of HIV Infection on Transplant Outcomes after Autologous Peripheral Blood Stem Cell Transplantation: A Retrospective Study of Japanese Registry Data.
    Yoshinaga N; Kanda J; Aisa Y; Hagiwara S; Mori T; Fukuda T; Ishida Y; Hashimoto H; Iwato K; Kanda Y; Kurokawa M; Nakazawa H; Ota S; Uchida N; Ichinohe T; Atsuta Y; Takaori-Kondo A
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1596-1601. PubMed ID: 29551446
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients.
    Caimi PF; William BM; Silva Rondon CH; Fu P; Cooper BW; Campagnaro EL; Gerson SL; Reese-Koc J; Fox R; Creger RJ; de Lima M; Lazarus HM
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1926-31. PubMed ID: 26087475
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors.
    Klyuchnikov E; Bacher U; Kröger NM; Hari PN; Ahn KW; Carreras J; Bachanova V; Bashey A; Cohen JB; D'Souza A; Freytes CO; Gale RP; Ganguly S; Hertzberg MS; Holmberg LA; Kharfan-Dabaja MA; Klein A; Ku GH; Laport GG; Lazarus HM; Miller AM; Mussetti A; Olsson RF; Slavin S; Usmani SZ; Vij R; Wood WA; Maloney DG; Sureda AM; Smith SM; Hamadani M
    Biol Blood Marrow Transplant; 2015 Dec; 21(12):2091-2099. PubMed ID: 26253007
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Differential prognostic impact of pretransplant comorbidity on transplant outcomes by disease status and time from transplant: a single Japanese transplant centre study.
    Kataoka K; Nannya Y; Ueda K; Kumano K; Takahashi T; Kurokawa M
    Bone Marrow Transplant; 2010 Mar; 45(3):513-20. PubMed ID: 19684632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.